Improvement of Animal Models and Development of Technologies for Stem Cell-Based Regenerative Medicine (SBIR)(R43/R44)
Sector: Commercial • Location: United States of America
Source: Grants.gov
This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop or improve technologies for obtaining, characterizing and testing animal and human stem cells and their derivatives as models for stem cell-based regenerative medicine using animal models. The program is intended to support
Project Information FAQ
Project Information
Want to explore the full details? View the full report
Participants
Sponsoring Agency | Obfuscated Data |
Company | Obfuscated Data |
Status
Original status | archived |
Taiyo status | Obfuscated Data |
Taiyo last update | 00-00-0000 |
Available timestamps | 00-00-0000 |
Available timestamp type | Obfuscated Data |
Contact
Contact name | Obfuscated Data |
Phone | 0000000000 |
ObfuscatedData@email.com | |
Address | Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data |
Description
Description | This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop or improve technologies for obtaining, characterizing and testing animal and human stem cells and their derivatives as models for stem cell-based regenerative medicine using animal models. The program is intended to support projects devoted to the creation of informative animal models for regenerative medicine, which will facilitate testing the safety and therapeutic potential of animal and human stem cells and their derivatives for pre-clinical evaluation. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cells and their derivatives, including production, characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications. The ultimate objective of these efforts should be to provide commercial products and technologies that can help develop future clinical therapies. |
Original sub-sector | Obfuscated |
Original Currency | USD |
Original budget | 000000000000000 |
Procurement method | Obfuscated Data |
Budget | 000000000000000 |
Location
Region | Obfuscated |
Country | Obfuscated |
State | Obfuscated Data |
County | Obfuscated |
Location | Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data |
Source
Source reliability | High |
Data quality score | 100% |
Source | Obfuscated Data |
URL | obfuscated_data,obfuscateddata.com |
More Details
Project Type | Obfuscated Data |
Article Published Date | Obfuscated Data |
